{
    "clinical_study": {
        "@rank": "124566", 
        "arm_group": {
            "arm_group_label": "Live attenuated measles/rubella combined vaccine", 
            "description": "Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey  is to assess the safety freeze-dried live attenuated measles and\n      rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated\n      measles and rubella combined vaccine \"Takeda\") in terms of the occurrence of unknown/known\n      adverse drug reactions and factors that may influence the safety of vaccinees after the\n      first vaccination."
        }, 
        "brief_title": "Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination", 
        "completion_date": {
            "#text": "April 2009", 
            "@type": "Actual"
        }, 
        "condition": "Measles/Rubella", 
        "condition_browse": {
            "mesh_term": [
                "Measles", 
                "Rubella"
            ]
        }, 
        "detailed_description": {
            "textblock": "This survey was designed to assess the safety of live attenuated measles and rubella\n      combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated measles\n      and rubella combined vaccine \"Takeda\") in terms of the occurrence of unknown/known adverse\n      drug reactions and factors that may influence the safety of vaccinees after the first\n      vaccination.\n\n      Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8\n      strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for\n      injection [Japanese Pharmacopoeia]), wherein a 0.5-mL portion is typically administered\n      subcutaneously as a single dose.\n\n      In addition, freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8\n      strain/TO-336 strain) should be used in accordance with the \"Regulations for Vaccination\"\n      and the \"Guidelines for Routine Vaccination.\""
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Vaccinees who meet both of the following conditions [1] and [2]:\n\n               1. Vaccinees who have no prior history of either measles or rubella vaccination and\n                  who received freeze-dried live attenuated measles and rubella combined vaccine\n                  (Schwarz FF-8 strain/TO-336 strain) as the initial vaccination\n\n               2. Vaccinees whose guardians are able to participate in a questionnaire survey on\n                  the health status of vaccinees after vaccination with freeze-dried live\n                  attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336\n                  strain)\n\n                  Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Measles/rubella"
            }
        }, 
        "enrollment": {
            "#text": "3493", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151773", 
            "org_study_id": "247-011"
        }, 
        "intervention": {
            "arm_group_label": "Live attenuated measles/rubella combined vaccine", 
            "description": "Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)", 
            "intervention_name": "Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)", 
            "intervention_type": "Drug", 
            "other_name": "Freeze-dried live attenuated measles and rubella combined vaccine \"Takeda\""
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 28, 2014", 
        "number_of_groups": "1", 
        "official_title": "Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine \"Takeda\" Special Drug Use Surveillance of Vaccinees After the First Vaccination", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "For each adverse event, the following will be investigated: [1] Name of adverse event, [2] date of onset, [3] seriousness (if pyrexia is observed, peak body temperature is recorded, and if rash is observed, severity is graded), [4] action taken for the adverse event, [5] outcome, and [6] causal relationship to freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)", 
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "For 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The overall frequency of adverse drug reactions is calculated.", 
                "measure": "Occurrence of adverse drug reactions (adverse events whose causal relationship to freeze-dried live attenuated measles and rubella combined vaccine [Schwarz FF-8 strain/TO-336 strain] cannot be ruled out)", 
                "safety_issue": "Yes", 
                "time_frame": "For 28 days"
            }, 
            {
                "description": "The frequency of adverse drug reactions by background factors of vaccinees is calculated.", 
                "measure": "Factors that may influence safety (including the presence/absence of vaccinees requiring careful examination before vaccination)", 
                "safety_issue": "Yes", 
                "time_frame": "For 28 days"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2006", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}